What Proto Axiom does

Proto Axiom is a Sydney-based private holding company and biotech company-creation platform founded in 2021. Rather than operating as a closed-end venture fund, it forms, owns, governs and finances wholly-owned biotech companies derived from Australian translational science sourced from universities (Sydney, UNSW, Monash, Griffith, Western Sydney, ANZAC Research Institute), medical research institutes, and the public health system. Capital deployment is milestone-gated across four explicit decision gates — Formation, Pre-clinical, Clinical and Inflection — releasing tranches against evidence rather than calendar dates. The platform provides a shared operating bench (~28 people across management, board, scientific advisory and strategic advisors, including 5 PhDs/MDs and 6 ex-operators) that rotates clinical, regulatory, IP, finance and governance capability across portfolio companies, with advisors drawn from Pfizer, Novo Nordisk, GSK, Novartis, Merck Serono and BMS.

The current portfolio comprises nine companies spanning therapeutics (Endo Axiom oral insulin via liver-targeting nanotechnology, Onyx Axiom topical antifungal via lyotropic liquid crystal delivery, JumpStart Fertility NAD+ platform with IVF media lead application, AdvanCell lead-212 alpha radiopharmaceuticals), diagnostics (SWAN Genomics plasmonic nanoantenna DNA sequencing), bioprocessing (Flo Axiom downstream purification materials), research tools (Herikin desktop RNA printer), biomanufacturing (Cellutech) and digital health (Amazing Gut Ins&Outs TGA-cleared at-home anorectal biofeedback device). Four portfolio programs are approaching clinical trials: Endo Axiom is IND-enabling, Onyx Axiom is in Phase IIb, JumpStart Fertility is preparing sibling-embryo trials, and AdvanCell reported 80% PSA50 response and 100% objective response in Phase 1b at ESMO October 2025, prompting Eli Lilly to expand its strategic oncology collaboration in February 2025.

Proto Axiom generates returns through equity appreciation in portfolio companies as they advance through milestone gates, supplemented by licensing revenue from individual programs. The company does not sell products or services to end customers; investor relations and pipeline development run through direct email outreach, earned media (Forbes, AFR), a low-frequency newsletter (Proto Axiom Connect), podcast appearances, and the Challenger Summit — Australia's largest life-sciences pitch day, which distributes A$500,000 annually in non-dilutive grants across two A$250K streams co-hosted with St Vincent's Curran Foundation, and serves as the primary sourcing vehicle for future portfolio companies. Capital base stands at A$45M+ deployed across the portfolio, with A$20M raised at an A$90M post-money valuation in March 2026 from a 33-investor base that includes Marc Benioff (Salesforce CEO) and Ajay Banga (World Bank president).

Name

Proto Axiom

Legal name

Proto Axiom Pty Ltd

Website

https://protoaxiom.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Proto Axiom is a Sydney-based private biotech company-creation platform (founded 2021) that forms, owns, governs and finances wholly-owned biotech companies from Australian translational science via a milestone-gated four-gate process, with nine portfolio companies spanning therapeutics, diagnostics, bioprocessing and digital health.

Ownership category

akta.pro rank

Product category

Biotech Venture Incubation

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

akta.pro secondary industries

Nonclinical Study Management & Regulatory Writing (IND-enabling) (HLAGAFAN), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Biotech company creation
• Translational science incubation
• Biomedical venture building
• Milestone-gated capital
• Biotech holding company

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Portfolio company equity returns: Proto Axiom forms, owns and operates biotech companies. Returns are generated through equity appreciation as portfolio companies advance through milestone gates, raise subsequent funding rounds at higher valuations, and achieve commercial or strategic exits (licensing, acquisition, IPO). The holding company structure means capital is permanent and recycled into companies as they hit gates — no fund-cycle-driven exit pressure. Early translation programs may also generate licensing revenue for the portfolio companies themselves.
2. Challenger Summit non-dilutive grants: The Challenger Summit flagship pitch program distributes A$500,000 in non-dilutive grants across two streams (A$250K each) to Australian researchers and founders. Grants are awarded to surface translational science before it reaches the conventional capital stack. Winners may separately enter commercial conversations with Proto Axiom about company formation and capital, but grant award itself involves no equity exchange.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Proto Axiom is a private Australian biotech company-creation platform that forms, owns and operates early-stage and clinical-stage biotechnology companies from translational Australian science. Capital is deployed tranche-by-tranche through a four-gate methodology (Formation, Pre-clinical, Clinical, Inflection) supported by a shared operating bench across clinical, regulatory, IP, finance and governance. The platform runs Challenger Summit, an annual pitch program distributing A$500,000 in non-dilutive grants across two streams as a proprietary sourcing pipeline for translational science.

Product overview

Proto Axiom is an Australian biotech company-creation platform that forms and operates biotechnology companies from Australian science. The platform encompasses nine portfolio companies spanning therapeutics (oral insulin, antifungals, NAD+ platforms, radiopharmaceuticals), diagnostics (DNA sequencing), bioprocessing (downstream purification), and digital health (medical devices). Proto Axiom also runs flagship programs including Challenger Summit (a A$500,000 pitch competition for life sciences) and Proto Axiom Connect (newsletter). The operating model provides shared bench capabilities across scientific diligence, clinical development, regulatory, IP, finance and governance to portfolio companies.

Differentiator

Problem solved

Functional benefit

Brands

• Challenger Summit: Australia's largest pitch day in life sciences, co-hosted by Proto Axiom and St Vincent's Curran Foundation. A$500,000 in non-dilutive grants awarded across two streams for biotech startups.
• Proto Axiom Connect
• Challenger Pitch for Health

Products and services

• Endo Axiom Portfolio company developing oral insulin as an oral biologic that does not require injection, with an IND application targeted in 2026. Targeted at diabetes patients who currently rely on injectable insulin therapy.
• SWAN Genomics Portfolio company operating a Next Generation Sequencing platform spun out of the Ramaciotti Centre for Genomics at UNSW Sydney. Targeted at researchers and clinical laboratories requiring scalable DNA sequencing services.
• Onyx Axiom Portfolio company developing a topical antifungal therapeutic. Targeted at patients with fungal skin and nail infections.
• JumpStart Fertility Portfolio company translating NAD+ biology into improved IVF media for assisted reproduction. Targeted at fertility clinics and IVF patients.
• Flo Axiom Portfolio company developing bioprocessing materials for biotechnology manufacturing. Targeted at biotechnology manufacturers and bioprocess operators.
• AdvanCell Portfolio company developing radiopharmaceuticals, including a Phase III-ready lead asset for metastatic castration-resistant prostate cancer. Targeted at oncology patients and nuclear medicine providers.
• Herikin Portfolio company developing an RNA printer that automates RNA synthesis. Targeted at research laboratories and biotechnology developers needing automated RNA production.
• Cellutech Portfolio company operating a biomanufacturing platform. Targeted at biotechnology manufacturers requiring scaled production capacity.
• Amazing Gut Portfolio company commercializing the Ins&Outs microbiome sampling device, which is TGA-cleared and targets the gut microbiome sampling market for consumers, clinicians and researchers.
• Challenger Summit Annual pitch program that distributes A$500,000 in non-dilutive grants across two streams (A$250K each) to Australian researchers and founders, and serves as a sourcing pipeline that may lead to commercial company-formation conversations with Proto Axiom. Targeted at Australian researchers, founders and translational scientists.

Quantifiable outcome

• 9 biotech companies formed since 2021, 5 as founding investor, with A$45M+ deployed
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• St Vincent's Curran FoundationcoreGTM or Marketing PartnerCo-host of Challenger Summit, Australia's largest life-sciences pitch day. The St Vincent's Discovery & Innovation 'Pitch for Health' grants stream (A$250K) is combined with Proto Axiom's own stream (A$250K) into a single national showcase. Open to teams from St Vincent's Hospital Sydney, Garvan Institute of Medical Research, and Victor Chang Cardiac Research Institute.
• Genea BiomedxcoreImplementation/ SI/ Consulting PartnerSydney-based GMP manufacturer for JumpStart Fertility's lead clinical application (IVF laboratory media). Genea Biomedx provides manufacturing capability for the NAD+ platform technology.
• Case BiosciencecoreImplementation/ SI/ Consulting PartnerMelbourne-based partner providing formulation expertise for JumpStart Fertility's IVF media platform.
• Western Sydney UniversitycoreStrategic or Co-development PartnerOrigin institution of Amazing Gut (Ins&Outs device) and Dr Jerry Zhou. Western Sydney University programs are eligible for the Proto Axiom Challenger Summit stream. Proto Axiom holds a venture-stage investment in Amazing Gut.
• UNSW Founders B10xcoreStrategic or Co-development PartnerCellutech emerged from the UNSW Founders B10x accelerator programme. Proto Axiom holds a venture-stage investment via the Bio 10x SAFE programme. Notes the founding team came from this cohort.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Curie.Bio: Curie.Bio is an emerging biotech company-creation platform that combines seed capital with a shared operating bench of pharma operators and scientific advisors. Conceptually analogous to Proto Axiom's four-gate formation model and shared-bench capability, though at an earlier stage and US-focused.
• Petri.bio: Petri is an early-stage biotech accelerator that sources and builds companies from frontier bio research, providing lab infrastructure and operating support. Comparable to Proto Axiom in the company-creation mission but at an earlier stage and focused on the US/Boston ecosystem.

Broad incumbents

• MPM Capital: MPM Capital is a biotech investment firm that both launches and invests in oncology and biomedical companies with active operating involvement. Comparable to Proto Axiom in company-creation and clinical-stage focus, though operating as a multi-fund platform rather than a single holding company.
• Roivant Sciences: Roivant Sciences is a clinical-stage biotech holding company that creates, acquires, and develops 'Vants' (subsidiary biotech companies) with shared operating infrastructure. Comparable to Proto Axiom in holding-company structure, clinical-stage portfolio focus, and capital-recycling model — though operating at much larger scale and US-listed.
• BridgeBio Pharma: BridgeBio is a commercial-stage biotechnology company that builds subsidiaries around genetically validated targets. Comparable in the multi-asset, holding-company approach to clinical development, though BridgeBio's portfolio is focused on a single therapeutic area (genetic diseases) versus Proto Axiom's modality and indication breadth.

Direct peers

• ARCH Venture Partners: ARCH Venture Partners is a leading biotech VC that co-founds and operates companies from frontier science. Comparable to Proto Axiom in translational sourcing and company-creation GTM, with similar operating-bench involvement, though at much larger scale and US-centric sourcing.
• Syncona: Syncona is a UK-listed biotech company-creation and investment trust that builds and owns biotech companies from academic science with permanent capital. Highly comparable to Proto Axiom in model — academic sourcing, company formation, milestone-gated deployment, long-horizon LP base — though operating from a UK/European sourcing base.
• Atlas Venture: Atlas Venture is a leading early-stage biotech venture firm that builds companies from academic science in the Boston/Cambridge ecosystem. Comparable to Proto Axiom in company-formation focus, but uses a traditional closed-end fund structure rather than Proto Axiom's permanent-capital holding company.
• Flagship Pioneering: Flagship Pioneering is the archetypal biotech company-creation platform — it originates, forms, and operates biotech companies (Moderna, Generate Biomedicines, Tessera Therapeutics) using a systematic platform analogous to Proto Axiom's holding-company model. Flagship's permanent-capital, milestone-gated approach and shared scientific/operating bench is the closest analogue to Proto Axiom's structure and GTM motion.

Regional players

• Brandon Capital: Brandon Capital is an Australian biotech VC manager (MRCF) that funds early-stage Australian biomedical research, and is also an investor in AdvanCell alongside Proto Axiom. Strong regional peer in the Australian translational ecosystem, with comparable sourcing base but operates as a traditional fund-of-funds/LP structure rather than a holding company.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/protoaxiom
• Xx.com/protoaxiom

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries5 records

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Proto Axiom